Population Pharmacokinetics Analysis of Regorafenib and Its Active Metabolites From the Phase III Correct Study of Metastatic Colorectal Cancer
Zuzana Jirakova Trnkova(Highlight Therapeutics (Spain)), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josep Tabernero(Deaconess Hospital), Antoine Adenis(Inserm), Salvatore Siena(University of Milan), Y. Humblet(UCLouvain Saint-Louis Brussels), Axel Grothey(Campbell Clinic), Stefanie Reif(Bayer (Germany)), Takayuki Yoshino(University of Tsukuba), Dirk Laurent(Menarini Group (Germany)), Laurent Mineur(Institut Sainte Catherine), Konstanze Diefenbach(Charité - Universitätsmedizin Berlin), Olivier Bouché(CHU Dijon Bourgogne), Frank Cihon(Alleanza Contro il Cancro), Alberto F. Sobrero(Ospedale Policlinico San Martino), H. Lenz(University of Southern California), Carlo Barone(Università Cattolica del Sacro Cuore), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Jean Smeets, Marc Ychou(Université de Montpellier)
Cited by 7
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k